Inhibition of Multidrug Resistance of Cancer Cells by CoDelivery of DNA Nanostructures and Drugs Using Porous Silicon Nanoparticles@Giant Liposomes

The co-delivery of molecular-targeted therapeutics for combination therapy is one of the hottest areas in biomedicine due to its ability to suppress drug toxicity and reduce drug resistance for effective cancer treatment. [ 1–6 ] Most of the targeted drugs, from monoclonal antibodies to small molecule kinase inhibitors, are still most effective in combination therapy. Combination of two or more drugs working synergistically [ 3,7 ] often produces an even greater response rate or survival time than each individual drug at its optimal dose. [ 8–14 ] In addition, the selectivity in targeting oncoproteins or oncogenes signifi cantly enhances the treatment effi ciency. [ 8 ] However, co-administration of therapeutics with high effi ciency, tunable ratio, and targeting selectivity into a single carrier represents a great challenge for the encapsulation and release technological point of view. Despite remarkable progress in formulating drugs combinations, substantial obstacles such as low drug loading effi cacy and low antitumor effi cacy are still remained unsolved. [ 8 ] Inhibition of Multidrug Resistance of Cancer Cells by Co-Delivery of DNA Nanostructures and Drugs Using Porous Silicon Nanoparticles@Giant Liposomes